TD Asset Management
MRVI icon

TD Asset Management’s Maravai LifeSciences MRVI Stock Holding History

TD Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-145,984
Closed -$474K – 1267
2025
Q4 		$474K Hold
145,984
– – ﹤0.01% 1176
2025
Q3 		$419K Buy
145,984
+81,326
+126% +$208K ﹤0.01% 1184
2025
Q2 		$156K Buy
+64,658
New +$136K ﹤0.01% 1180
2022
Q4 		– Sell
-25,155
Closed -$639K – 1475
2022
Q3 		$639K Sell
25,155
-22,900
-48% -$575K ﹤0.01% 1252
2022
Q2 		$1.36M Sell
48,055
-33,400
-41% -$1.06M ﹤0.01% 1119
2022
Q1 		$2.87M Hold
81,455
– – ﹤0.01% 982
2021
Q4 		$3.41M Hold
81,455
– – ﹤0.01% 983
2021
Q3 		$4M Buy
81,455
+22,500
+38% +$1.1M ﹤0.01% 875
2021
Q2 		$2.59M Buy
58,955
+34,979
+146% +$1.36M ﹤0.01% 1022
2021
Q1 		$855K Buy
+23,976
New +$794K ﹤0.01% 1299

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TD Asset Management's MRVI Position: Q1 2026 in Review

TD Asset Management sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 145,984 shares — an estimated $474K sold.

TD Asset Management first reported a position in MRVI in Q1 2021 and held it in 10 quarters. The position peaked at $4M in Q3 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • TD Asset Management reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
  • TD Asset Management sold 145,984 Maravai LifeSciences shares in Q1 2026, an estimated $474K.
  • TD Asset Management first reported a position in Maravai LifeSciences in Q1 2021 and held it in 10 quarters.
  • TD Asset Management's Maravai LifeSciences position peaked at $4M in Q3 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.